Skip to main content

Malignancy clinical trials at UCSF
1 in progress, 1 open to new patients

  • Abatacept as GVHD Prophylaxis Phase 2

    open to eligible people ages 6 years and up

    This is a phase II multi-center, randomized, double blind, placebo-controlled trial. The investigators are doing this study to see if a new drug, abatacept, can be used together with a calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate to provide better protection against Acute Graft versus Host Disease (aGvHD) without causing more infections. Funding Source - FDA OOPD

    Oakland, California and other locations